Luminogenic cytochrome P450 assays
- 21 July 2006
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 2 (4) , 629-645
- https://doi.org/10.1517/17425255.2.4.629
Abstract
Luminogenic cytochrome P450 (CYP) assays couple CYP enzyme activity to firefly luciferase luminescence in a technology called P450-GloTM (Promega). Luminogenic substrates are used in assays of human CYP1A1, -1A2, -1B1, -2C8, -2C9, -2C19, -2D6, -2J2, -3A4, -3A7, -4A11, -4F3B, -4F12 and -19. The assays detect dose-dependent CYP inhibition by test compounds against recombinant CYP enzymes or liver microsomes. Induction or inhibition of CYP activities in cultured hepatocytes is measured in a nonlytic approach that leaves cells intact for additional analysis. Luminogenic CYP assays offer advantages of speed and safety over HPLC and radiochemical-based methods. Compared with fluorogenic methods the approach offers advantages of improved sensitivity and decreased interference between optical properties of test compound and CYP substrate. These homogenous assays are sensitive and robust tools for high-throughput CYP screening in early drug discovery.Keywords
This publication has 61 references indexed in Scilit:
- Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introductionBiochemistry and Molecular Biology Education, 2006
- High throughput P450 inhibition screens in early drug discoveryDrug Discovery Today, 2005
- Predicting in vivo drug interactions from in vitro drug discovery dataNature Reviews Drug Discovery, 2005
- Cell-based models to study hepatic drug metabolism and enzyme induction in humansExpert Opinion on Drug Metabolism & Toxicology, 2005
- HIGH VOLUME BIOASSAYS TO ASSESS CYP3A4-MEDIATED DRUG INTERACTIONS: INDUCTION AND INHIBITION IN A SINGLE CELL LINEDrug Metabolism and Disposition, 2005
- DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOSDrug Metabolism and Disposition, 2004
- THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVEDrug Metabolism and Disposition, 2003
- Human CYPs: in vivo and clinical aspectsDrug Metabolism Reviews, 2002
- The Safety of Newly Approved MedicinesPublished by American Medical Association (AMA) ,1999
- The Human Hepatic Cytochromes P450 Involved in Drug MetabolismCritical Reviews in Toxicology, 1992